Data is not available at this time.
CloudMD Software & Services Inc. is a healthcare technology company operating across North America with a diversified portfolio spanning three core segments: Clinic Services & Pharmacies, Digital Health Services, and Enterprise Health Solutions. The company's revenue model is built on providing integrated health services, including operating physical and hybrid medical clinics, retail pharmacies, and a suite of proprietary digital health platforms. Its offerings target both individual consumers and enterprise clients, delivering solutions such as mental health support, healthcare navigation, telemedicine, and occupational health services. Within the competitive Healthcare Information Services sector, CloudMD aims to differentiate itself by creating an interconnected ecosystem that bridges traditional in-person care with digital tools. This strategy positions the company to address the growing demand for hybrid healthcare models, which combine physical clinics with virtual care capabilities. Its market position is that of a niche integrator, seeking to consolidate various aspects of patient care—from initial consultation through pharmacy services and chronic disease management—into a seamless experience. Key digital assets like the MyHealthAccess patient portal and the Health and Wellness intervention platform form the technological backbone of this strategy, enabling data-driven care coordination.
For FY 2023, CloudMD reported revenue of CAD 90.9 million, demonstrating its ability to generate significant top-line figures. However, the company faced substantial profitability challenges, posting a net loss of CAD 83.2 million and negative operating cash flow of CAD 11.6 million. The negative EPS of CAD 0.28 reflects the current stage of its business cycle, where investments and integration costs are likely outweighing operational efficiencies. Capital expenditures were modest at CAD 2.0 million, suggesting a focus on leveraging existing assets rather than significant new infrastructure investment.
The company's current earnings power is constrained, as evidenced by the significant net loss. The negative operating cash flow indicates that core operations are not yet self-funding, requiring external capital to sustain activities. The capital efficiency metrics will be a critical area for improvement as the company works to integrate its acquisitions and streamline its multi-segment operations to achieve economies of scale and a path toward positive cash generation.
CloudMD's balance sheet shows a cash position of CAD 11.4 million against total debt of CAD 23.3 million, indicating a leveraged financial structure. The net debt position, combined with negative cash flow from operations, highlights liquidity constraints and suggests a reliance on external financing or asset sales to meet ongoing obligations. This financial profile is characteristic of a growth-stage company in a capital-intensive sector, but it necessitates careful capital management.
The company does not pay a dividend, which is consistent with its growth-focused strategy that prioritizes reinvestment into the business. Historical growth has been driven largely by acquisitions to build its integrated platform. The current financial results suggest a phase of consolidation and optimization rather than aggressive top-line expansion, as management likely focuses on improving the profitability of the existing asset base.
With a market capitalization of approximately CAD 12.2 million, the market is valuing the company at a significant discount to its annual revenue. This valuation reflects investor skepticism regarding the company's path to profitability and its ability to service its debt. The beta of 1.37 indicates higher volatility than the market, which is typical for small-cap technology stocks with uncertain earnings trajectories.
CloudMD's strategic advantage lies in its integrated care model, which combines physical clinics, pharmacies, and digital tools. The outlook is contingent on its ability to successfully integrate its diverse acquisitions, achieve cost synergies, and demonstrate a clear roadmap to profitability. Success will depend on executing its hybrid healthcare strategy effectively in a competitive market while managing its financial leverage and improving operational cash flows to ensure long-term sustainability.
Company Annual Financial FilingsTSXV Disclosures
show cash flow forecast
| Fiscal year | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | 2035 | 2036 | 2037 | 2038 | 2039 | 2040 | 2041 | 2042 | 2043 | 2044 | 2045 | 2046 | 2047 | 2048 | |
INCOME STATEMENT | ||||||||||||||||||||||||||
| Revenue growth rate, % | NaN | |||||||||||||||||||||||||
| Revenue, $ | NaN | |||||||||||||||||||||||||
| Variable operating expenses, $m | NaN | |||||||||||||||||||||||||
| Fixed operating expenses, $m | NaN | |||||||||||||||||||||||||
| Total operating expenses, $m | NaN | |||||||||||||||||||||||||
| Operating income, $m | NaN | |||||||||||||||||||||||||
| EBITDA, $m | NaN | |||||||||||||||||||||||||
| Interest expense (income), $m | NaN | |||||||||||||||||||||||||
| Earnings before tax, $m | NaN | |||||||||||||||||||||||||
| Tax expense, $m | NaN | |||||||||||||||||||||||||
| Net income, $m | NaN | |||||||||||||||||||||||||
BALANCE SHEET | ||||||||||||||||||||||||||
| Cash and short-term investments, $m | NaN | |||||||||||||||||||||||||
| Total assets, $m | NaN | |||||||||||||||||||||||||
| Adjusted assets (=assets-cash), $m | NaN | |||||||||||||||||||||||||
| Average production assets, $m | NaN | |||||||||||||||||||||||||
| Working capital, $m | NaN | |||||||||||||||||||||||||
| Total debt, $m | NaN | |||||||||||||||||||||||||
| Total liabilities, $m | NaN | |||||||||||||||||||||||||
| Total equity, $m | NaN | |||||||||||||||||||||||||
| Debt-to-equity ratio | NaN | |||||||||||||||||||||||||
| Adjusted equity ratio | NaN | |||||||||||||||||||||||||
CASH FLOW | ||||||||||||||||||||||||||
| Net income, $m | NaN | |||||||||||||||||||||||||
| Depreciation, amort., depletion, $m | NaN | |||||||||||||||||||||||||
| Funds from operations, $m | NaN | |||||||||||||||||||||||||
| Change in working capital, $m | NaN | |||||||||||||||||||||||||
| Cash from operations, $m | NaN | |||||||||||||||||||||||||
| Maintenance CAPEX, $m | NaN | |||||||||||||||||||||||||
| New CAPEX, $m | NaN | |||||||||||||||||||||||||
| Total CAPEX, $m | NaN | |||||||||||||||||||||||||
| Free cash flow, $m | NaN | |||||||||||||||||||||||||
| Issuance/(repurchase) of shares, $m | NaN | |||||||||||||||||||||||||
| Retained Cash Flow, $m | NaN | |||||||||||||||||||||||||
| Pot'l extraordinary dividend, $m | NaN | |||||||||||||||||||||||||
| Cash available for distribution, $m | NaN | |||||||||||||||||||||||||
| Discount rate, % | NaN | |||||||||||||||||||||||||
| PV of cash for distribution, $m | NaN | |||||||||||||||||||||||||
| Current shareholders' claim on cash, % | NaN |